Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors


Indomethacin RCT for covid-19 – features and conclusions

Written by | 9 Sep 2021

The RCT provides objective evidence of the effect of indomethacin and confirms the absence of adverse gastrointestinal effects; a future study could investigate indomethacin in severe covid-19, according… read more.

Randomised controlled trial of indomethacin for covid-19

Written by | 8 Sep 2021

Rapid resolution of symptoms and improved oxygen saturation were key features of the response to indomethacin compared with paracetamol, according to Dr Rajan Ravichandran and Professor Krishna Kumar…. read more.

Indomethacin provides rapid relief from covid symptoms

Written by | 7 Sep 2021

The interim results of a randomised comparison between indomethacin and paracetamol in covid-19 showed stark differences in efficacy, confirming the positive results of early trials of indomethacin. IMI… read more.

Prophylaxis with ivermectin and the next steps

Written by | 22 May 2021

Interview and article by Christine Clark. Ivermectin should be used for prophylaxis and treatment of covid-19 throughout India, according to Dr Suryakant (Head of the Department of Respiratory… read more.

Choosing and using ivermectin for covid-19 in India

Written by | 19 May 2021

Interview and article by Christine Clark. In the Northern in Indian state of Uttar Pradesh, ivermectin has been in use for treatment and prophylaxis of covid-19 since August… read more.

DCGI (India) approves Sputnik V COVID 19 vaccine for emergency use in India – Dr Reddy’s Laboratories

Written by | 25 Apr 2021

Dr. Reddy’s Laboratories Ltd. announced that it has received the permission from the Drug Controller General of India (DCGI) to import the Sputnik vaccine into India for restricted… read more.

AstraZeneca Pharma India announces marketing approval for Tagrisso (Osimertinib)

Written by | 11 Mar 2021

AstraZeneca Pharma India Limited announced that it has received marketing approval for Tagrisso (Osimertinib) for adjuvant treatment after complete tumour resection in patients with non-small cell lung cancer… read more.

Newsletter Icon

Subscribe for our mailing list

If you're a healthcare professional you can sign up to our mailing list to receive high quality medical, pharmaceutical and healthcare E-Mails and E-Journals. Get the latest news and information across a broad range of specialities delivered straight to your inbox.


You can unsubscribe at any time using the 'Unsubscribe' link at the bottom of all our E-Mails, E-Journals and publications.